Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus price objective of $26.75 for the company, according to Zacks. Zacks has also assigned Takeda Pharmaceutical an industry rank of 75 out of 256 based on the ratings given to its competitors.
Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. ValuEngine cut shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Finally, Goldman Sachs Group reaffirmed a “buy” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, March 19th.
Shares of NYSE:TAK traded up $0.48 on Friday, reaching $17.11. 1,068,350 shares of the company’s stock were exchanged, compared to its average volume of 3,517,479. Takeda Pharmaceutical has a twelve month low of $15.50 and a twelve month high of $21.95. The firm has a market cap of $26.29 billion, a PE ratio of 33.55 and a beta of 0.69. The company has a quick ratio of 0.82, a current ratio of 1.22 and a debt-to-equity ratio of 0.92.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Read More: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.